Portal de Periódicos da CAPES

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

2007; Elsevier BV; Volume: 111; Issue: 4 Linguagem: Inglês

10.1182/blood-2007-06-096396

1528-0020

Jamshid S. Khorashad, Dragana Milojković, Puja Mehta, Mona Anand, Sara Ghorashian, Alistair Reid, Valeria De Melo, Anna Babb, Hugues de Lavallade, Eduardo Olavarría, David Marín, John M. Goldman, Jane F. Apperley, Jaspal Kaeda,

Eosinophilic Disorders and Syndromes

We sought kinase domain (KD) mutations at the start of treatment with dasatinib in 46 chronic myeloid leukemia (CML) patients resistant to or intolerant of imatinib. We identified BCR-ABL mutant subclones in 12 (26%) cases and used pyrosequencing to estimate subsequent changes in their relative size after starting dasatinib. Four patients lost their mutations, which remained undetectable, 3 patients retained the original mutation or lost it only transiently, 3 lost their original mutations but acquired a new mutation (F317L), and 2 developed another mutation (T315I) in addition to the original mutation within the same subclone. This study shows that expansion of a mutant Ph-positive clone that responds initially to a second generation tyrosine kinase inhibitor may be due either to late acquisition of a second mutation in the originally mutated clone, such as the T315I, or to acquisition of a completely new mutant clone, such as F317L.